From mboxrd@z Thu Jan 1 00:00:00 1970 From: "Felix Goff" Subject: Hurry do not let yourself to miss this incredible offer. Fresh news Date: Mon, 22 Jan 2007 23:01:55 +0000 (UTC) Message-ID: <01c73e4f$7a5e3000$6c822ecf@transittingatrium> Mime-Version: 1.0 Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Return-path: Date: Mon, 22 Jan 2007 18:02:27 -0060 List-Unsubscribe: , List-Archive: List-Post: List-Help: List-Subscribe: , Sender: linux-pm-bounces@lists.osdl.org Errors-To: linux-pm-bounces@lists.osdl.org To: linux-pm@osdl.org List-Id: linux-pm@vger.kernel.org = Grab Human BIOSYSTEMS INC. (HBSC.OB) stock today. = THE ALARM IS STRATED! AND IT IS GOING TO BURST. = = Monday will be the day when your gains will be really SOAR. = It's getting growth almost every hour! So you can triple your balance any t= ime. = We are sure thet you had not opportunity like that before. = = Friday price: JAN 18 - $0.08 = On monday 22 January it will - 0.13$ at least and 0.20$ at most (not bad fo= r a day) = = Call your brokers in order they get it immediately. = = Do not miss your chance.MORE THAN 83% EVERY DAY! = HBSC just released this news. U.S. Patent Office to Grant Human BioSystems its Fifth Patent, "Composition= s, Methods and Apparatuses for Preserving Platelets" Monday January 22, 7:00 am ET PALO ALTO, CALIFORNIA--(MARKET WIRE)--Jan 22, 2007 -- Human BioSystems (HBS= ) (OTC BB:HBSC.OB - News), developer of preservation platforms for organs, = blood platelets and other biomaterials, announced today that the U.S. Paten= t Office has allowed HBS' patent application for platelet preservation enti= tled "Compositions, Methods and Apparatuses for Preserving Platelets." A pa= tent number is expected to be issued in the near future. HBS has been granted four previous patents related to organ, platelet and b= iological material preservation. Including the patent to be issued, HBS' pa= tent portfolio is as follows: 1. Methods and Apparatus for Preserving Biological Materials - U.S. Patent = # 6,413,713 2. Methods and Apparatuses for Preserving Platelets - U.S. Patent # 6,828,0= 90 3. Methods and Solutions for Storing Donor Organs - U.S. Patent # 7,029,839 4. Preservation of Blood Platelets with Citrate - U.S. Patent # 7,083,910 5. Compositions, Methods and Apparatuses for Preserving Platelets - U.S. Pa= tent number to be issued "All of the patents we have received thus far serve to strengthen our intel= lectual property protection as we progress toward commercializing our techn= ologies and bringing them to market," explained Dr. David Winter, President= of Human BioSystems. The latest patent to be awarded is among four patents that relate to the pr= eservation of blood platelets, a blood component critical to cancer patient= s that have undergone chemotherapy/radiation treatments. Platelet infusions= are necessary for a period of time following such cancer treatments to mai= ntain adequate platelet counts. The lack of platelets could increase the ch= ances of bleeding. "HBS hopes to extend the preservation time of platelets beyond current stan= dards while maintaining quality and safety by utilizing patented cooling me= thods not achieved by others thus far in the commercial blood banking indus= try. If successful, this could result in hundreds of millions of dollars in= savings to blood centers and hospitals worldwide," concluded Dr. Winter. HBS is headquartered in Palo Alto, California with research facilities in M= ichigan. Certain statements contained herein are "forward-looking'' statements (as s= uch term is defined in the Private Securities Litigation Reform Act of 1995= ). Because such statements include risks and uncertainties, actual results = may differ materially from those expressed or implied by such forward-looki= ng statements. Factors that could cause results to differ materially from t= hose expressed or implied by such forward-looking statements include, but a= re not limited to, results from ongoing research and development as well as= clinical studies, failure to obtain regulatory approval for the Company's = products, if required, failure to develop a product based on the Company's = technology, failure of any such products to compete effectively with existi= ng products, the inability to find a strategic partner or to consummate a r= elationship with a potential strategic partner on acceptable terms, the eff= ectiveness of protection of the Company's intellectual property, and other = factors discus! sed in filings made by the Company with the Securities and Exchange Commis= sion. TAKE THIS INCREDIBLE HBSC.OB right now. =